COVID-19 Campus Safeguard Program eligibility
* The offer to join the COVID-19 Campus Safeguard Program is valid only for academic institutions in the US from January 1 through March 31, 2021. $5 promotional pricing is for on-campus CLIA certified clinical labs performing the Advanta Dx SARS-CoV-2 RT-PCR Assay and offered through June 2021 if accounts commit to a contractual obligation to purchase and receive a minimum volume of tests before December 31, 2021, if the account requires a Biomark HD instrument. Pricing for off-campus testing depends on the level of service desired and other terms and conditions. Pricing does not apply to instrument pricing, shipping, installation, training, service plans or other consumables. No additional discounts apply with this promotion. This offer does not apply to private clinical laboratories and public health laboratories. Learn more at fluidigm.com/covid-19-campus.
The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is a real-time Reverse Transcription (RT) PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in saliva specimens collected without preservatives in a sterile container from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to Laboratories which are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meet requirements to perform high complexity tests.
Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in saliva specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.
Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. Negative results for SARS-CoV-2 RNA from saliva should be confirmed by testing of an alternative specimen type if clinically indicated.
The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is only for use under the Food and Drug Administration's Emergency Use Authorization.
For In Vitro Diagnostic Use. For Use Under Emergency Use Authorization Only. Rx Only.
This test has not been FDA cleared or approved.
This test has been authorized by FDA under an EUA for use by authorized laboratories.
This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogen.
This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Information in this publication is subject to change without notice.
Patent and license information: fluidigm.com/legal/notices.
Trademarks: Fluidigm, the Fluidigm logo, Advanta and Biomark are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners.
©2021 Fluidigm Corporation. All rights reserved. 01/2021